- cafead   Nov 04, 2019 at 07:32: PM
via Daiichi Sankyo’s short-lived interest in the U.S. pain management market has officially come to an end, as the company's new CEO continues shifting its focus to oncology and the industry reels from the nation’s opioid crisis.
article source
article source